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a b s t r a c t
Background: Global efforts to adequately monitor safety of new vaccines for pregnant women in low and
middle-income countries (LMICs) are needed. The Global Alignment of Immunization Safety Assessment
in pregnancy (GAIA) project recently published case definitions based on levels of diagnostic certainty for
pregnancy- and neonatal outcomes and maternal vaccination. As a preliminary step to assessing the
applicability of these definitions in LMICs, WHO selected sites and conducted a feasibility assessment
to evaluate their ability to identify and classify selected outcomes (preterm birth, neonatal death, neona-
tal invasive bloodstream infection (NI-BSI), stillbirth) and maternal vaccination.
Methods: Candidate sites were initially screened using a questionnaire. For each outcome, eligible sites
were asked to retrospectively identify and collect information for three individuals born in 2016.
Subsequently, outcomes were classified by level of diagnostic certainty.
Results: Fifty-one sites (15 countries) were screened; 32 of them (9 countries) participated in the assess-
ment and identified 315 subjects with the outcomes of interest. Twenty-four sites (8 countries) identified
at least one subject per outcome and agreed to continue participating. The majority (80%) of preterm
births, neonatal deaths, and NI-BSI subjects, but only 50% of stillbirths, could be assessed for diagnostic
certainty. The main reasons for not classifying stillbirths were insufficient information to distinguish
between antepartum and intrapartum stillbirth (29%); or that not all data for one subject fit into a single
level of diagnostic certainty (35%). Forty-nine percent of mothers were considered vaccinated, 6% not-
vaccinated, and vaccination status could not be assessed in 44% of them.
Discussion: GAIA case definitions for four neonatal outcomes and maternal vaccination were successfully
piloted in 24 sentinel sites across four WHO regions. Our assessment found that modification of the still-
birth definition could help avoid potential misclassification. Vaccine safety monitoring in LMICs will ben-
efit from systematic recording of all vaccinations during pregnancy.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The goal of maternal vaccination is to transfer protective immu-
nity to infants too young to benefit directly from primary immu-
nization, and to protect the fetus from the effects of maternal or
early life infection [1]. Tetanus, pertussis and influenza vaccines
are already recommended by the World Health Organization
(WHO) [2–4]; whilst new vaccines against hepatitis E, Zika virus,
respiratory syncytial virus (RSV) and Group B Streptococcus
(GBS) are under clinical evaluation. Low and middle-income coun-
tries (LMICs), where perinatal and infant mortality rates are higher,
would particularly benefit from maternal vaccination with these
new vaccines. A potential threat to maternal vaccination programs,
however, is the fear of a perceived association between vaccination
and common antenatal complications such as spontaneous abor-
tion and stillbirth. It is critical that those countries that may benefit
the most from new vaccines develop pregnancy intervention safety
monitoring beyond passive surveillance.
The Global Alignment of Immunization Safety Assessment in
pregnancy (GAIA) project, funded by the Bill and Melinda Gates
Foundation, has recently proposed standard definitions of
key obstetric and neonatal terms, maternal immunization and
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gestational age using the Brighton Collaboration method [5–8].
Each case definition is stratified into multiple levels of diagnostic
certainty, where Level 1 is the highest attainable level (maximum
specificity), and Level 2 and 3 have a stepwise increase in sensitiv-
ity, while retaining an acceptable level of specificity [9]. Diagnostic
certainty of level 4 or above is considered insufficient to confirm
the case definition [10]. These attempts at standardizing case def-
initions may help enable meaningful comparisons across studies
[11]. The Global Advisory Committee on Vaccine Safety (GACVS)
and Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)
highlighted the need for field validation and assessment of the
applicability of the GAIA case definitions in high-, middle- and
low-income settings [12].
WHO is planning to conduct a pregnancy multi-country collab-
orative (MCC) study to assess the applicability of GAIA definitions
in LMICs. The long-term goal of this work is to assess the feasibility
of conducting well-designed collaborative observational studies to
monitor the safety of new vaccines targeted for use in pregnant
women in LMICs as part of the WHO Global Vaccine Safety
Initiative (GVSI) [13–15]. A first multi-center international
proof-of-concept study investigated the association between
Guillain-Barre Syndrome and the 2009 H1N1 pandemic influenza
vaccine using a network of hospital-based sentinel sites in
high- and middle-income countries. This study successfully
demonstrated its political and scientific feasibility [16]. A subse-
quent proof-of-concept study [17], aimed at addressing the WHO’s
Global Vaccine Safety Blueprint’s [14] strategic goal of enhanced
pharmacovigilance capacity, was performed under the umbrella
of the GVSI [18]. This study further demonstrated that a global
hospital-based network with participation of LMICs, could effec-
tively evaluate rare and serious vaccine adverse events, and could
even potentially be used to characterize risk differences between
vaccine strains [17].
As a preliminary step to select eligible sites for the pregnancy
MCC study, we conducted a feasibility assessment to identify sites
able to access data of acceptable quality to detect and classify
selected neonatal outcomes and maternal vaccination by GAIA
levels of diagnostic certainty.
2. Methods
Selection of primary, secondary and tertiary care centers was a
multi-step process: (1) Preliminary site identification was followed
by (2) a screening questionnaire to select sites for the feasibility
assessment, and a (3) feasibility assessment to select sites for the
pregnancy MCC study (Fig. 1).
2.1. Step 1: preliminary site identification
We selected as potential sites those that participated in the pre-
vious MCC project [17], including sites in two high income coun-
tries in order to facilitate data quality control. We also included
additional sites from LMICs identified through WHO regional and
country offices and Ministries of Health. The inclusion criteria
included the existence of a functional national vaccine pharma-
covigilance system willing to strengthen its capacity to monitor
vaccine safety during pregnancy, an obstetrics department with
1000 deliveries per year, a pediatric ward, patient records
(paper/electronic), and a clinician willing to serve as focal point
for the project (Suppl_1 First step in selection).
2.2. Step 2: screening questionnaire
Sites were asked to complete screening questions on hospital
characteristics (including whether it is a primary, secondary or
tertiary care center), patient records and operational aspects
(Suppl_2 Screening questionnaire). Exclusion criteria included lack
of access to individual patient charts, computers, or internet.
2.3. Step 3: feasibility assessment
Diagnostic capacity and data access were further assessed in
screened sites through the conduct of a simulation exercise.
The following four GAIA case definitions were selected: preterm
birth [9], neonatal death [19], neonatal invasive bloodstream infec-
tion (BSI) [20], and stillbirth [10] (Suppl_3 GAIA case definitions).
For this feasibility assessment, these outcomes were selected for
their relatively high incidence; necessity to have a mother-baby
linkage; occurrence within one month of birth (more likely to be
recorded in hospital records); requiring gestational age assessment
(a key component for case definition of several pregnancy-related
outcomes); or requiring laboratory data. Among neonatal infec-
tions, only the case definition for neonatal invasive BSI was
assessed; meningitis and respiratory infections were not [20]. Both
the antepartum and intrapartum stillbirth case definitions were
assessed. For neonatal death, no distinction was made based on
‘type’ of neonatal death (extremely preterm, preterm, term) in this
assessment. However, the ability to collect gestational age was
assessed.
The GAIA definition for maternal immunization was also
selected, [19] given the need to ascertain vaccine exposures for
vaccine safety monitoring (Suppl_3 GAIA case definitions).
Tetanus-containing vaccines were chosen as the preferred expo-
sure of interest, as they are widely used in pregnant women in
LMICs [21].
Between May and July 2017, sites were requested to complete
case report forms (CRFs) in predesigned Epi InfoTM or Microsoft
ExcelTM data entry screens for at least one, but preferably three ret-
rospectively identified subjects for each of the four pregnancy out-
comes (leading to a maximum of twelve subjects per site) (Suppl_4
CRFs). Sites were instructed to select the first three recorded cases
in 2016 among neonates born in 2016 from their archives or data-
bases. ICD codes were provided for sites using ICD codes (Suppl_4
CRFs). Data collection on subjects was restricted to the data items
part of the GAIA case definitions; therefore, additional data (such
as singleton versus multiple deliveries) were not collected. Details
on the data sources used for subject identification were collected.
Sites were first sent the CRFs in Epi InfoTM format, and only if
problems in correctly installing the software were encountered
they were sent the CRFs in ExcelTM format. Instructions on how to
complete the CRFs were provided, without formal training
(Suppl_4 CRFs). Cases were then automatically classified by level
of diagnostic certainty, using a case classification algorithm
designed by the research team and programmed in SAS  v9.4 [22].
To inform future study preparation, including training and
resources, sites were also asked to indicate the level of difficulty
in completing the CRFs (ranging from very easy to very difficult),
staff’s qualification, and time required to identify cases and com-
plete CRFs.
Our analysis was based on a convenience sample size. The
choice to request three subjects per outcome per site was a prag-
matic one and was not based on any statistical sample size
considerations.
Descriptive statistics were calculated in ExcelTM.
2.4. Outcome assessment measures and site eligibility criteria used in
the feasibility assessment
An ‘identified subject’ was defined as a subject for whom any
information had been completed in the CRF for one of the four
selected pregnancy-related outcomes. A ‘classified case’ was
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defined as an identified subject for whom sufficient information
was provided to apply a level of diagnostic certainty listed in the
respective GAIA case definition.
Sites were considered eligible for participation in the pregnancy
MCC study if at least one case was classifiable for each selected
outcome, demonstrating minimum diagnostic capacity and data
access.
2.5. Post hoc sensitivity analysis
The stillbirth case definition reads ‘‘Delivery of an infant
reported to have no signs of life at birth (no spontaneous move-
ments, no umbilical cord pulse, no heartbeat, no cry or sponta-
neous respirations, no chest movement)” [10]. We interpreted
this to mean that information on the absence of each sign of life
should be reported. We subsequently learned from the authors of
this case definition that information is not required for all signs
(i.e. it is acceptable if one or more signs are not recorded). There-
fore, a post hoc sensitivity analysis with a less strict definition
was performed, requiring absence of at least one sign of life
(instead of all).
2.6. Ethics
Data were collected from existing records by the clinician in
charge of the patients and identified as focal point for the preg-
nancy MCC project. No identifying information was collected, and
patients were not contacted. Therefore, the feasibility assessment
was considered exempted from ethical clearance.
3. Results
3.1. Site selection
Initially, 51 sites in 15 countries were identified (Albania,
Australia, Burkina Faso, China, Ghana, India, Iran, Nepal, Rwanda,
Fig. 1. Flow of site selection. aDid not meet selection criteria: Lack of access to patient charts (n = 7), to computers (n = 2), to internet (n = 6). There may be multiple exclusion
criteria for one site. bWithdrew because of a very low rate of vaccination during pregnancy. cFor the outcomes neonatal death, neonatal invasive bloodstream infection and
preterm birth only; stillbirth not used as a selection criterion. Withdrew after selection. dWithdrew as they experienced difficulties reaching the minimum required
diagnostic capacity and data access.
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Singapore, South Africa, Spain, Tanzania, Togo and Zimbabwe) and
invited to complete the screening questionnaire. Thirty-seven sites
in 12 countries met the screening criteria and were invited to par-
ticipate in the assessment. Thirty-two out of these 37 sites, in nine
countries, returned data (response rate 86%, Fig. 1). Of these, six
sites did not identify at least one subject per outcome and were
excluded. For the remaining 26 sites, at least one case could be
classified for neonatal death, neonatal invasive BSI and preterm
birth; for six sites of these 26 sites, none of the stillbirth subjects
could be classified. After identifying some limitations to the still-
birth case definition (described below), classification of at least
one stillbirth case was no longer used as a selection criterion.
Two more sites withdrew after completing the feasibility assess-
ment, leaving 24 sites from 8 countries eligible to participate in
any future study, including one primary care center, four sec-
ondary hospitals, 18 tertiary hospitals and one regional health
institution. Site characteristics are listed in Table 1 and Suppl_5
(Methods and sources of data for subject identification). Sources
cited for subject identification include: admissions and discharge
books, delivery register, clinic report book, medical record depart-
ment register, and hospital records,
3.2. Piloting selected GAIA outcome definitions
3.2.1. Subject identification and case classification by level of
diagnostic certainty
Overall, a total of 72–87 subjects per outcome were identified
(Table 2). Twenty-six of 32 sites participating in the feasibility
assessment identified at least one subject per pregnancy outcome.
Eighty-four percent of the identified neonatal death subjects could
be classified as well as 83% of the preterm birth and 77% of the
neonatal invasive BSI subjects, whereas only 51% of the identified
stillbirth subjects could be classified (in the main analysis). The
most frequent levels of diagnostic certainty were Level 2 for neona-
tal death (81%) and neonatal invasive BSI (51%), and Level 3 for pre-
term birth (69%) and stillbirth (41%).
3.2.2. Classification issues
Stillbirth was the case definition with the highest number of
non-classified subjects. There were three main reasons for non-
classification of stillbirths (Table 3). First, sometimes it was ques-
tionable whether the identified subject was indeed stillborn (8%;
e.g. Apgar score not 0). Second, it was not always clear whether a
stillbirth was an antepartum or an intrapartum stillbirth (29%).
However, as there are separate case definitions for these two
events, this distinction is required for classification. Third, some-
times evidence on level of diagnostic certainty was not the same
across all the data elements provided (35%). The stillbirth case def-
inition consisted of a combination of data elements on absence of
signs of life, prenatal (lack of) fetal cardiac activity and movement,
delivery (attended, non-attended), physical examination of the
stillborn and gestational age [10] (Suppl_3 GAIA case definitions).
The way these data elements must be ascertained differs between
levels of diagnostic certainty. Combinations of elements that
reflect different levels of diagnostic certainty prohibited
classification.
Table 1
Description of the eligible sites.
WHO region country Type of facility Nr of beds Nr of annual deliveries Discharge diagnosis stored electronically
African Region
Ghana
GH-A Secondary 193 1700 NR
GH-B Secondary 80 1200 NR
GH-C Secondary 326 8600 NR
GH-D Secondary 352 5000 NR
South Africa
SA-A Tertiary 3000 21,500–22,000 NR
Tanzania
TA-A Tertiary 250 NR Yes
TA-B Tertiary 163 3000–4000 Yes
TA-C Tertiary 156 10,000–11,000 Yes
TA-D Tertiary 350 4500 No
Zimbabwe
ZI-A Primary 32 5000 NR
ZI-B Tertiary 210 1700 NR
European Region
Spain
SP-A Regional health institution NR NR Yes
South-East Asian Region
India
IN-A Tertiary 1800 5800 Yes
IN-B Tertiary 1500 3300 Yes
IN-C Tertiary 1237 6100 No
IN-D Tertiary 1023 3500 No
IN-E Tertiary 2032 2500 Yes
IN-F Tertiary 1390 8500 No
IN-G Tertiary 766 3000 Yes
Nepal
NE-A Tertiary 580 8000 Yes
NE-B Tertiary 763 10,000 In process
Eastern Mediterranean Region
Iran
IR-A Tertiary 122 6000 NR
IR-B Tertiary 380 1500 NR
IR-C Tertiary 230 9900 No
NR: not reported by the site.
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The sensitivity analysis with a less strict interpretation of the
‘signs of life’ section of the stillbirth case definition resulted in
the classification of one additional stillbirth case, leading to a
minor increase in the percentage of classified cases (from 51% to
53%) (Table 2).
Reasons for non-classification of neonatal death, neonatal inva-
sive BSI and preterm birth were illogical dates (n = 17), insufficient
information (n = 6), missing date of birth (n = 8), or not meeting the
case definition (e.g. gestational age >37 weeks for preterm (n = 3),
age at death (n = 5) or age at infection onset >28 days (n = 7)). No
issues with the applicability of these three case definitions were
identified.
3.2.3. Maternal vaccination status
For each identified subject, sites were requested to report
whether the mother received any vaccination during pregnancy.
This question could be answered with ‘Yes’ (49%), ‘No’ (6%), or
‘Unknown’ (44%); sites were explicitly instructed to only answer
’No’ if there was documented evidence of no vaccination. Among
vaccinated women from whom vaccination information was
retrieved, 99 (68%) of the cases were classified as Level 3 (report
of vaccination during pregnancy, but no formal recording avail-
able), 37 (27%) as Level 2 (date of immunization recorded in med-
ical record, details of disease against which was vaccinated), and
eight (6%) reached Level 1 (data of immunization recorded in
Table 2
Subjects identified and cases classified in the feasibility assessment.
Preterm birth n(%) Neonatal deaths n(%) Neonatal invasive
BSI n(%)
Stillbirth n(%) Stillbirth
(SA) n(%)
Maternal immunization
n(%)
Total subjects identified 87 74 82 72 72 144*
Cases classified among subjects identified** 72 (83) 62 (84) 63 (77) 37 (51) 38 (53) 144 (1 0 0)
GAIA Level 1 (highest) 8 (11) 12 (19) 26 (41) 4 (11) 5 (13) 8 (6)
GAIA Level 2 14 (19) 50 (81) 32 (51) 5 (14) 5 (13) 37 (26)
GAIA Level 3 50 (69) 0 (0) 5 (8) 15 (41) 15 (39) 99 (69)
GAIA Level 4 (lowest) NA NA NA 13 (35) 13 (34) NA
GAIA: Global Alignment of Immunization Safety Assessment in pregnancy; NA: not applicable; SA: sensitivity analysis.
* Maternal immunization status was assessed for all 315 subjects (100%); 144 (46%) were identified by the sites as exposed to maternal immunization (i.e. question on
maternal immunization exposure was answered with ‘‘Yes”).
** Total may not tally to 100% due to rounding.
Table 3
Examples of reasons why subjects identified as stillborn in the assessment could not be classified according to the GAIA case definition [21] *.
Examples from the assessment
Unclear if there was a stillbirth
Signs of life at birth(n = 6)  Sign of life at birth (n = 1)
 Spontaneous movements present at birth (n = 1)
 Apgar score not 0 (n = 5)
Missing information on at least one sign of life(n = 13)  Signs of life at birth unknown (n = 3)
 Spontaneous movement unknown (n = 5)
 Umbilical cord pulse unknown (n = 6)
 Heartbeat unknown (n = 4)
 Respiration unknown (n = 4)
 Crying unknown (n = 5)
 Apgar score unknown (n = 5)
Sensitivity analysis
Missing information on all signs of life (n = 3)  Missing information on all signs of life (n = 3)
Unclear if the stillbirth was ante- or intrapartum
Lack of prenatal data (n = 10)  On foetal movement (through prenatal ultrasound, maternal report, physical exam of mother,
radiology) (n = 7)
 On foetal cardiac activity (through prenatal ultrasound, auscultation or Doppler) (n = 7)
Lack of information on whether physical exam was consistent
with intrapartum vs. antepartum death (n = 15)
 Unknown whether physical exam was consistent with intrapartum or antepartum death (N = 9)
 Physical exam was consistent with both intrapartum and antepartum death (N = 5)
 Physical exam consistent with neither intrapartum nor antepartum death (n = 1)
Mixed information (n = 7)  Physical exam consistent with antepartum death, but with foetal cardiac activity (n = 3)
 Physical exam consistent with antepartum death, but with radiology findings not consistent with
intrauterine death (n = 3)
 Physical exam consistent with intrapartum death, but with no foetal cardiac activity and move-
ment (n = 2)
Evidence accepted at higher levels of diagnostic certainty not accepted at lower levels
L3: Attended delivery and GA L3 (n = 25)  All deliveries reported in the feasibility assessment were attended. For stillbirth L3, only non-
attended deliveries with verbal report are eligible; therefore, none of the subjects fulfil the criteria
for L3. Consequently, none of the subjects with gestational age L3 (only eligible for stillbirth L3)
could be classified.
L4: Physical exam and GA (n = 25)  Subjects reported as stillborn but where the foetus was ‘‘not available for physical examination
after birth”, or subjects where ‘‘maternal information [was] insufficient to assess gestational age”
can qualify for L4. In our study, certain subjects could not be classified as Level 1–3 (for example
subjects with no signs of life at birth but for whom it was unclear if the stillbirth was ante- or
intrapartum). However, for most of these subjects a physical examination was performed after
birth and gestational age could be assessed. Consequently, these subjects were not eligible for L4.
GA: gestational age; Lx: Level x.
* More than one reason may apply.
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medical record, details of vaccine, including lot number) (Suppl_3
GAIA case definitions).
3.3. Feedback on CRF completion
CRFs were completed in Epi InfoTM (n = 14) or ExcelTM (n = 18).
Among 32 sites that completed the feasibility assessment, 23 sites
(72%) provided feedback. Among 12 sites that used Epi InfoTM, 11
sites indicated that the CRFs were ‘easy’ to complete, and one site
that they were ‘very easy’. For sites that used ExcelTM, data was col-
lected by outcome; sites reported more difficulties in completing
the CRFs, but no major difference between outcomes were
observed (Table 4).
3.4. Resources
Among the 32 sites that completed the feasibility assessment,
23 sites (72%) provided information on resources required for sub-
ject identification and CRF completion. In these sites, the identifi-
cation of subjects was mostly done by physicians (n = 19 sites),
nurses (n = 12) and researchers (n = 7). The type of staff reported
required for CRF completion was very similar.
Table 4 shows the time reported required to identify one sub-
ject and to complete one CRF. No important differences were seen
in time needed between sites that reported identifying subjects
through codes (e.g. ICD codes) and those that did not use codes.
Large variations were observed in the time required to identify a
subject, ranging from minutes to several hours, and occasionally
1–2 working days. The median average time required to complete
one CRF was approximately one hour.
4. Discussion
We conducted a pilot assessment of GAIA case definitions for
four neonatal outcomes and maternal vaccination as part of a study
site selection process. Out of 51 contacted sites, 24 sites were
judged eligible for participation in a future study after successfully
demonstrating their ability to access and produce data of accept-
able quality to identify and classify pregnancy-related outcomes
and maternal vaccination exposure using the GAIA case definitions.
We found a relatively low level of ascertainment of the vaccina-
tion status of the mothers that may have been related to the retro-
spective nature of the study and the limited resources available. A
frequent reason for absence of vaccination records was because
receipt of a vaccine during pregnancy is routinely written on moth-
ers’ antenatal records or take-home antenatal card, which were not
always available in this retrospective assessment that relied on
medical records, and in which no contact with the mother was
sought. Better mother-baby linkage or additional follow-up during
the study would likely increase the number of mothers with a ver-
ified vaccination status.
Furthermore, most maternal vaccination cases were classified
as Level 3 (68%), i.e. ‘‘receipt of vaccination during pregnancy,
but no formal recording of immunization available” [19]. Thus,
the level of recording needs to be improved considerably. The issue
of retrospective vaccination status ascertainment has been previ-
ously recognized in vaccine safety investigations. One proposed
solution was to prepare a list of events of interest for vaccine safety
investigations and routinely ascertain exposure status during hos-
pitalization for patients with a diagnosis that matches this list [23].
We learned that retrospective subject identification required a
labor-intensive manual search of archives at most sites, as elec-
tronic records were not widely available. In addition, multiple sites
indicated that if ICD coding was used, this was often incomplete or
inaccurate. Consequently, in this study, ICD codes were not neces-
sarily helpful for subject identification and archives still needed to
be searched.
No major problems with interpreting the GAIA case definitions
other than those described for stillbirth were identified. Almost
half the identified stillbirths could not be classified, due to limita-
tions to the collected data or the case definition. Frequently, infor-
mation to distinguish between antepartum and intrapartum
stillbirth was insufficient (or conflicting). Additionally, some still-
births could not be classified because not all data for one subject
fit into a single level of diagnostic certainty. The GAIA classification
of diagnostic certainty for stillbirth could be improved by accept-
ing ‘higher level’ evidence (e.g. attended deliveries; prenatal ultra-
sound to detect fetal cardiac activity) at lower levels of diagnostic
certainty (that currently require e.g. non-attended deliveries; aus-
cultation to detect fetal cardiac activity). Moreover, the stillbirth
case definition requires clarity on how to read the ‘‘OR”/”AND”
Table 4
Level of difficulty of completing CRFs in ExcelTM, and range and median of average time reported by sites participating in feasibility assessment to identify one subject and to
complete one CRF.
Outcome
Preterm birth Neonatal death Neonatal invasive BSI Stillbirth
Difficulty of completing CRFs in Excel
N sites 11 9 10 10
Very easy 1 1 2 1
Easy 3 2 2 2
NEND 2 1 0 1
Difficult 5 5 6 4
Very difficult 0 0 0 2
Average time to identify one subject (codes)
N sites 10 7 9 10
Range* 30 min to 5 h 25 min to 1 day 20 min to 2 days 1 min to 5 h
Median 1 h 15 min 2 h 1 h 15 min 1 h
Average time to identify one subject (no codes)
N sites 13 15 14 13
Range 2 min to >1 working day 2 min to >1 working day 2 min to 2 days 5 min to >1 working day
Median <2 h <2 h <2 h <2 h
Average time to complete one CRF
N sites 23 22 22 23
Range 5 min to 1 day 5 min to 1 day 5 min to 1 day 5 min to 1 day
Median 1 h 50 min 1 h 1 h
BSI: bloodstream infection; CRF: case report form; h: hour; min: minute; N: neonatal.
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combinations within each level of diagnostic certainty, and the
part on signs of life. The sensitivity analysis resulted in the classi-
fication of only one additional case.
We noted that a mismatch in levels of evidence of different data
elements can also arise with the maternal immunization definition,
where different levels of evidence of pregnancy are matched with
different levels of vaccination evidence.
We are aware of two other studies implementing the GAIA case
definitions. A study at a Health and Demographic Surveillance Sys-
tem (HDSS) site in Uganda piloted five maternal and five neonatal
GAIA definitions (hypertensive disorders, maternal death, path-
ways to preterm birth, postpartum hemorrhage and non-
reassuring fetal status; congenital anomalies, neonatal death,
neonatal infection, preterm birth and stillbirth). From this study,
it was concluded that capacity to use the GAIA definitions exists
even in settings with very limited resources, although heterogene-
ity by type of health facility existed [24,25]. Results were presented
at a conference, so details were limited [24]. Another study evalu-
ating whether cases from routine care and clinical trials can be
classified according to 10 GAIA definitions in high income settings
is ongoing [24].
Our feasibility assessment presents several limitations. Due to
time constraints, no automated logical checks were included in
the CRFs, which may have affected data quality and, indirectly,
the proportion of identified classifiable cases. Similarly, only a
few sites were contacted for data clarification and cleaning pur-
poses when illogical data entries were found. Logical checks will
be essential in future studies, to ensure data quality. Furthermore,
as this was a feasibility assessment, a maximum of three subjects
per pregnancy outcome per site were included, therefore, caution
is needed when drawing conclusions, e.g. on the percentage of
cases classified at each level, especially at site level. In addition,
sites may have selected subjects with maximum information for
inclusion in the exercise. When the actual study will be conducted
and all cases collected during a given period are included, we will
have a better reflection of the level of diagnostic certainty to be
expected in situations of real-world surveillance. Preliminary sites
were not selected to be representative for each country, but were
initially chosen based on the criteria described in Suppl_1 (First
step in selection). Further site selection following the feasibility
assessment was based on data quality (access to sufficiently
detailed clinical records); which comes at a cost of reduced gener-
alizability and possibly biasing future surveillance activities to
sites with better quality data.
The feasibility assessment was a first step towards identifying
sites that could participate in a larger international collaborative
study aimed at fully assessing the applicability of the GAIA case
definitions in the real-world setting of LMICs and estimating the
minimum detectable risk of selected neonatal outcomes in relation
to the maternal vaccination status.
To investigate future potential safety signals in a timely man-
ner, adverse events following immunization would need to be
resolved with additional studies, and if verified, further prioritized,
so that infrastructure can be developed accordingly [12]. This
should be done in the context of both pharmacovigilance systems
development and maternal, newborn and child health surveillance
[12]. The GAIA case definitions, once field tested and validated, can
form an integral part of improving data quality and standardiza-
tion [11]. Field testing and validation of the GAIA case definitions
in the real-world setting of LMICs will be important in evaluating
their applicability and generalizability in settings where linkage
of the necessary information to identify a potential maternal
immunization-related safety outcome can be particularly challeng-
ing. Such data will also inform about the occurrence rates of those
conditions of interest and will allow estimating the required sam-
ple size of future active surveillance studies.
5. Conclusion
In this feasibility assessment, the GAIA case definitions for four
neonatal outcomes and maternal immunization were successfully
piloted in 24 sentinel sites across four WHO regions. These sites
have been selected for the pregnancy MCC study. Modification of
the GAIA stillbirth definition could help avoid potential misclassi-
fication. Retrospective subject identification is resource-intensive,
as archives must be searched manually at most of the selected
sites. Given the state of most institutions’ record-keeping systems
in our study, a retrospective study was deemed to be less capable
of providing complete case assessments. Also, a retrospective
design would limit opportunities to build institutional capacities.
In this context, a prospective approach may provide better oppor-
tunities to improve institutional data collection and recording sys-
tems, including mother-baby data linkage and systematic
recording of all vaccinations administered during pregnancy, hence
strengthening capacities for public health surveillance activities
and research.
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